EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

被引：0
|
作者：
Gratacos-Masmitja, J. [1 ]
Turkiewicz, A. [2 ]
Dokoupilova, E. [3 ,4 ]
Gellett, A. M. [5 ]
Sprabery, T. [5 ]
Geneus, V. J. [5 ]
Constantin, A. [6 ]
机构：
[1] Univ Hosp Parc Tauli Sabadell, Barcelona, Spain
[2] Rheumatol Associates PC, Birmingham, AL USA
[3] Med Plus Sro, Uherske Hradiste, Czech Republic
[4] Univ Vet & Pharmaceut Sci, Dept Pharmaceut, Fac Pharm, Brno, Czech Republic
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Hosp Pierre Paul Riquet, Toulouse, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0411
引用
收藏
页码：1154 / 1154
页数：1
相关论文
共 50 条
  • [21] Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
    Laura C. Coates
    Philip Mease
    Andris Kronbergs
    Cameron Helt
    David Sandoval
    So Young Park
    Bernard Combe
    Peter Nash
    Atul Deodhar
    Clinical Rheumatology, 2022, 41 : 3261 - 3261
  • [22] SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL
    Orbai, A. M.
    Gratacos-Masmitja, J.
    Dokoupilova, E.
    Combe, B.
    Constantin, A.
    Gellett, A. M.
    Sprabery, A. T.
    Birt, J.
    Geneus, V.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1705 - 1706
  • [23] Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C.
    Mou, J.
    Moriarty, S. R.
    Lee, C.
    Gladman, D.
    Satler, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [24] Fifty two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S.
    Lee, C.
    Gladman, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 33
  • [25] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
    Mease, Philip J.
    Okada, Masato
    Kishimoto, Mitsumasa
    Shuler, Catherine L.
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan R.
    Lee, Chin H.
    Gladman, Dafna D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [26] The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
    Deodhar, Atul
    Gladman, Dafna
    Bolce, Rebecca
    Sandoval, David
    Park, So Young
    Leage, Soyi Liu
    Nash, Peter
    Poddubnyy, Denis
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
  • [27] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
    Coates, L. C.
    Kronbergs, A.
    Sprabery, A. T.
    Park, S. Y.
    Combe, B.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1153 - 1154
  • [28] A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR(S)
    Nash, P.
    Kirkham, B.
    Okada, M.
    Rahman, P.
    Combe, B.
    Adams, D. H.
    Kerr, L. N.
    Lee, C. H.
    Shuler, C. L.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 135
  • [29] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
    van der Heijde, Desiree
    Gladman, Dafna D.
    Kishimoto, Mitsumasa
    Okada, Masato
    Rathmann, Suchitrita S.
    Moriarty, Susan R.
    Shuler, Catherine L.
    Carlier, Hilde
    Benichou, Olivier
    Mease, Philip J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (03) : 367 - 377
  • [30] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Carter, K.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1136 - 1137
12345